| Identification | Back Directory | [Name]
4-Methyl Erlotinib Hydrochloride | [CAS]
1346601-52-2 | [Synonyms]
OSI-597
Erlotinib-9
4-methyl Erlotinib
Erlotinib iMpurity G
Erlotinib impurities406
Erlotinib 4-Methyl Analog
Azilsartan medoxomil impurity248
4-Methyl Erlotinib Hydrochloride
Erlotinib Hydrochloride iMpurity 8
N-(3-Ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
N-(3-Ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
4-Quinazolinamine, N-(3-ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)-
N-(3-ETHYNYL-4-METHYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)QUINAZOLIN-4-AMINE HCL
N-(3-ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)quizolin-4-aminehydrochloride
N-(3-ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride
N-[(3-Ethynyl-4-Methyl)phenyl]-6,7-bis(2-Methoxyethoxy)-4-quinazolinaMine Hydrochloride
Erlotinib impurity 15/N-(3-ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride
Erlotinib impurity GQ: What is
Erlotinib impurity G Q: What is the CAS Number of
Erlotinib impurity G Q: What is the storage condition of
Erlotinib impurity G | [Molecular Formula]
C23H25N3O4 | [MDL Number]
MFCD32201999 | [MOL File]
1346601-52-2.mol | [Molecular Weight]
407.46 |
| Chemical Properties | Back Directory | [Melting point ]
224-228°C (dec.) | [Boiling point ]
567.5±50.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), DMSO, Methanol (Slightly) | [form ]
Solid | [pka]
5.33±0.30(Predicted) | [color ]
Pale Pink to Pale Brown |
| Hazard Information | Back Directory | [Uses]
Erlotinib (E625000) derivative as internal standard for HPLC. | [Biological Activity]
4-methyl erlotinib is an analog of erlotinib by the addition of a methyl group at the four position of the phenyl group. erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (egfr) [1].the epidermal growth factor receptor (egfr) autocrine pathway has been important for cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread [2].erlotinib inhibits egfr-associated kinase activity by binding to the egf-activated receptor, with the phenyl group at one end sequestered in a hydrophobic pocket of the kinase domain and the ether linkages at the opposite end projecting into solvent [1].erlotinib can prolong survival in patients with non–small-cell lung cancer after first-line or second-line chemotherapy [3]. | [References]
[1] stamos, j. ,sliwkowski, m.x. and eigenbrot, c. structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. the journal of biological chemisty 277(48), 46265-46272 (2002).
[2] ciardiello f, tortora g. a novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[j]. clinical cancer research, 2001, 7(10): 2958-2970.
[3] shepherd f a, rodrigues pereira j, ciuleanu t, et al. erlotinib in previously treated non–small-cell lung cancer[j]. new england journal of medicine, 2005, 353(2): 123-132. |
|
|